One major contributor to osteoporosis is estrogen deficiency, which is prevalent in postmenopausal women. Estrogen plays a vital role in maintaining bone density by inhibiting bone resorption and ...

Inhibiting bone resorption via an effect on the RANK/RANKL/OPG signaling pathway (see following section); Enhancing bone formation by prolonging the lifespan of osteoblast cells (Figure 1A).

“Our findings suggest that injectable hydrogels with localized anti-catabolic drug delivery can complement systemic ...

Current therapies for the prevention and treatment of osteoporosis are limited by efficacy and patient compliance. RANKL/osteoprotegerin/RANK signaling regulates bone resorption and is essential ...

Osteoporosis is a disabling skeletal disorder that is characterized by decreased bone strength, predisposing patients to increased risk of bone fracture. Peak bone mass (maximum bone strength and ...

Osteoporosis is a disease in which bone resorbs faster than it is formed, gradually weakening its structure over time and ...

Osteoporosis, which affects approximately ... bone begins to weaken when bone resorption exceeds bone formation. Circulating osteoclast precursor cells exacerbate bone resorption and loss by ...

Bones are the living tissue on which the human skeleton is constructed and play a key role in enabling physical movements.

The discovery of a family with sequence similarity 102 member A (Fam102a) protein as a novel bone remodeling factor that ...

Researchers have combined injections of a novel hydrogel with systemic osteoporosis drugs in rats, achieving rapid local ...

By modulating both bone formation and resorption, iSN40 offers a potential new approach for the treatment of osteoporosis. Osteoporosis leads to reduced bone density and an increased risk of ...